Global Liposomal Doxorubicin Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2024

  • receipt Report ID : 161033
  • calendar_today Published On: Apr, 2019
  • file_copy Pages: 109
  • list Pharmaceuticals and Healthcare

Liposome doxorubicin is a commonly used anthracycline anti-tumor drug, and is one of the first-line drugs for ovarian cancer.

Scope of the Report:

In North America, the highest incidence of sarcoma, ovarian cancer, breast and liver cancer, and several other cancers is the highest. North America has become a major market due to the existence of advanced healthcare facilities and a high level of patient awareness of the various available treatments.

The worldwide market for Liposomal Doxorubicin is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.

This report focuses on the Liposomal Doxorubicin in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

Market Segment by Manufacturers, this report covers

Johnson & Johnson

Pfizer

Sun Pharmaceutical

Cadila Pharmaceuticals

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia etc.)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

Intravenous Infusion

Injection

Market Segment by Applications, can be divided into

Academic

Hospitals

Other

There are 15 Chapters to deeply display the global Liposomal Doxorubicin market.

Chapter 1, to describe Liposomal Doxorubicin Introduction, product scope, market overview, market opportunities, market risk, market driving force;

Chapter 2, to analyze the top manufacturers of Liposomal Doxorubicin, with sales, revenue, and price of Liposomal Doxorubicin, in 2016 and 2017;

Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;

Chapter 4, to show the global market by regions, with sales, revenue and market share of Liposomal Doxorubicin, for each region, from 2013 to 2018;

Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;

Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;

Chapter 12, Liposomal Doxorubicin market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;

Chapter 13, 14 and 15, to describe Liposomal Doxorubicin sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

Table of Contents

1 Market Overview

1.1 Liposomal Doxorubicin Introduction

1.2 Market Analysis by Type

1.2.1 Intravenous Infusion

1.2.2 Injection

1.3 Market Analysis by Applications

1.3.1 Academic

1.3.2 Hospitals

1.3.3 Other

1.4 Market Analysis by Regions

1.4.1 North America (United States, Canada and Mexico)

1.4.1.1 United States Market States and Outlook (2013-2023)

1.4.1.2 Canada Market States and Outlook (2013-2023)

1.4.1.3 Mexico Market States and Outlook (2013-2023)

1.4.2 Europe (Germany, France, UK, Russia and Italy)

1.4.2.1 Germany Market States and Outlook (2013-2023)

1.4.2.2 France Market States and Outlook (2013-2023)

1.4.2.3 UK Market States and Outlook (2013-2023)

1.4.2.4 Russia Market States and Outlook (2013-2023)

1.4.2.5 Italy Market States and Outlook (2013-2023)

1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

1.4.3.1 China Market States and Outlook (2013-2023)

1.4.3.2 Japan Market States and Outlook (2013-2023)

1.4.3.3 Korea Market States and Outlook (2013-2023)

1.4.3.4 India Market States and Outlook (2013-2023)

1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)

1.4.4 South America, Middle East and Africa

1.4.4.1 Brazil Market States and Outlook (2013-2023)

1.4.4.2 Egypt Market States and Outlook (2013-2023)

1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)

1.4.4.4 South Africa Market States and Outlook (2013-2023)

1.4.4.5 Nigeria Market States and Outlook (2013-2023)

1.5 Market Dynamics

1.5.1 Market Opportunities

1.5.2 Market Risk

1.5.3 Market Driving Force

2 Manufacturers Profiles

2.1 Johnson & Johnson

2.1.1 Business Overview

2.1.2 Liposomal Doxorubicin Type and Applications

2.1.2.1 Product A

2.1.2.2 Product B

2.1.3 Johnson & Johnson Liposomal Doxorubicin Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.2 Pfizer

2.2.1 Business Overview

2.2.2 Liposomal Doxorubicin Type and Applications

2.2.2.1 Product A

2.2.2.2 Product B

2.2.3 Pfizer Liposomal Doxorubicin Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.3 Sun Pharmaceutical

2.3.1 Business Overview

2.3.2 Liposomal Doxorubicin Type and Applications

2.3.2.1 Product A

2.3.2.2 Product B

2.3.3 Sun Pharmaceutical Liposomal Doxorubicin Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.4 Cadila Pharmaceuticals

2.4.1 Business Overview

2.4.2 Liposomal Doxorubicin Type and Applications

2.4.2.1 Product A

2.4.2.2 Product B

2.4.3 Cadila Pharmaceuticals Liposomal Doxorubicin Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

3 Global Liposomal Doxorubicin Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)

3.1 Global Liposomal Doxorubicin Sales and Market Share by Manufacturer (2016-2017)

3.2 Global Liposomal Doxorubicin Revenue and Market Share by Manufacturer (2016-2017)

3.3 Market Concentration Rate

3.3.1 Top 3 Liposomal Doxorubicin Manufacturer Market Share in 2017

3.3.2 Top 6 Liposomal Doxorubicin Manufacturer Market Share in 2017

3.4 Market Competition Trend

4 Global Liposomal Doxorubicin Market Analysis by Regions

4.1 Global Liposomal Doxorubicin Sales, Revenue and Market Share by Regions

4.1.1 Global Liposomal Doxorubicin Sales and Market Share by Regions (2013-2018)

4.1.2 Global Liposomal Doxorubicin Revenue and Market Share by Regions (2013-2018)

4.2 North America Liposomal Doxorubicin Sales and Growth Rate (2013-2018)

4.3 Europe Liposomal Doxorubicin Sales and Growth Rate (2013-2018)

4.4 Asia-Pacific Liposomal Doxorubicin Sales and Growth Rate (2013-2018)

4.5 South America Liposomal Doxorubicin Sales and Growth Rate (2013-2018)

4.6 Middle East and Africa Liposomal Doxorubicin Sales and Growth Rate (2013-2018)

5 North America Liposomal Doxorubicin by Countries

5.1 North America Liposomal Doxorubicin Sales, Revenue and Market Share by Countries

5.1.1 North America Liposomal Doxorubicin Sales and Market Share by Countries (2013-2018)

5.1.2 North America Liposomal Doxorubicin Revenue and Market Share by Countries (2013-2018)

5.2 United States Liposomal Doxorubicin Sales and Growth Rate (2013-2018)

5.3 Canada Liposomal Doxorubicin Sales and Growth Rate (2013-2018)

5.4 Mexico Liposomal Doxorubicin Sales and Growth Rate (2013-2018)

6 Europe Liposomal Doxorubicin by Countries

6.1 Europe Liposomal Doxorubicin Sales, Revenue and Market Share by Countries

6.1.1 Europe Liposomal Doxorubicin Sales and Market Share by Countries (2013-2018)

6.1.2 Europe Liposomal Doxorubicin Revenue and Market Share by Countries (2013-2018)

6.2 Germany Liposomal Doxorubicin Sales and Growth Rate (2013-2018)

6.3 UK Liposomal Doxorubicin Sales and Growth Rate (2013-2018)

6.4 France Liposomal Doxorubicin Sales and Growth Rate (2013-2018)

6.5 Russia Liposomal Doxorubicin Sales and Growth Rate (2013-2018)

6.6 Italy Liposomal Doxorubicin Sales and Growth Rate (2013-2018)

7 Asia-Pacific Liposomal Doxorubicin by Countries

7.1 Asia-Pacific Liposomal Doxorubicin Sales, Revenue and Market Share by Countries

7.1.1 Asia-Pacific Liposomal Doxorubicin Sales and Market Share by Countries (2013-2018)

7.1.2 Asia-Pacific Liposomal Doxorubicin Revenue and Market Share by Countries (2013-2018)

7.2 China Liposomal Doxorubicin Sales and Growth Rate (2013-2018)

7.3 Japan Liposomal Doxorubicin Sales and Growth Rate (2013-2018)

7.4 Korea Liposomal Doxorubicin Sales and Growth Rate (2013-2018)

7.5 India Liposomal Doxorubicin Sales and Growth Rate (2013-2018)

7.6 Southeast Asia Liposomal Doxorubicin Sales and Growth Rate (2013-2018)

8 South America Liposomal Doxorubicin by Countries

8.1 South America Liposomal Doxorubicin Sales, Revenue and Market Share by Countries

8.1.1 South America Liposomal Doxorubicin Sales and Market Share by Countries (2013-2018)

8.1.2 South America Liposomal Doxorubicin Revenue and Market Share by Countries (2013-2018)

8.2 Brazil Liposomal Doxorubicin Sales and Growth Rate (2013-2018)

8.3 Argentina Liposomal Doxorubicin Sales and Growth Rate (2013-2018)

8.4 Colombia Liposomal Doxorubicin Sales and Growth Rate (2013-2018)

9 Middle East and Africa Liposomal Doxorubicin by Countries

9.1 Middle East and Africa Liposomal Doxorubicin Sales, Revenue and Market Share by Countries

9.1.1 Middle East and Africa Liposomal Doxorubicin Sales and Market Share by Countries (2013-2018)

9.1.2 Middle East and Africa Liposomal Doxorubicin Revenue and Market Share by Countries (2013-2018)

9.2 Saudi Arabia Liposomal Doxorubicin Sales and Growth Rate (2013-2018)

9.3 UAE Liposomal Doxorubicin Sales and Growth Rate (2013-2018)

9.4 Egypt Liposomal Doxorubicin Sales and Growth Rate (2013-2018)

9.5 Nigeria Liposomal Doxorubicin Sales and Growth Rate (2013-2018)

9.6 South Africa Liposomal Doxorubicin Sales and Growth Rate (2013-2018)

10 Global Liposomal Doxorubicin Market Segment by Type

10.1 Global Liposomal Doxorubicin Sales, Revenue and Market Share by Type (2013-2018)

10.1.1 Global Liposomal Doxorubicin Sales and Market Share by Type (2013-2018)

10.1.2 Global Liposomal Doxorubicin Revenue and Market Share by Type (2013-2018)

10.2 Intravenous Infusion Sales Growth and Price

10.2.1 Global Intravenous Infusion Sales Growth (2013-2018)

10.2.2 Global Intravenous Infusion Price (2013-2018)

10.3 Injection Sales Growth and Price

10.3.1 Global Injection Sales Growth (2013-2018)

10.3.2 Global Injection Price (2013-2018)

11 Global Liposomal Doxorubicin Market Segment by Application

11.1 Global Liposomal Doxorubicin Sales Market Share by Application (2013-2018)

11.2 Academic Sales Growth (2013-2018)

11.3 Hospitals Sales Growth (2013-2018)

11.4 Other Sales Growth (2013-2018)

12 Liposomal Doxorubicin Market Forecast (2018-2023)

12.1 Global Liposomal Doxorubicin Sales, Revenue and Growth Rate (2018-2023)

12.2 Liposomal Doxorubicin Market Forecast by Regions (2018-2023)

12.2.1 North America Liposomal Doxorubicin Market Forecast (2018-2023)

12.2.2 Europe Liposomal Doxorubicin Market Forecast (2018-2023)

12.2.3 Asia-Pacific Liposomal Doxorubicin Market Forecast (2018-2023)

12.2.4 South America Liposomal Doxorubicin Market Forecast (2018-2023)

12.2.5 Middle East and Africa Liposomal Doxorubicin Market Forecast (2018-2023)

12.3 Liposomal Doxorubicin Market Forecast by Type (2018-2023)

12.3.1 Global Liposomal Doxorubicin Sales Forecast by Type (2018-2023)

12.3.2 Global Liposomal Doxorubicin Market Share Forecast by Type (2018-2023)

12.4 Liposomal Doxorubicin Market Forecast by Application (2018-2023)

12.4.1 Global Liposomal Doxorubicin Sales Forecast by Application (2018-2023)

12.4.2 Global Liposomal Doxorubicin Market Share Forecast by Application (2018-2023)

13 Sales Channel, Distributors, Traders and Dealers

13.1 Sales Channel

13.1.1 Direct Marketing

13.1.2 Indirect Marketing

13.1.3 Marketing Channel Future Trend

13.2 Distributors, Traders and Dealers

14 Research Findings and Conclusion

15 Appendix

15.1 Methodology

15.2 Data Source

List of Tables and Figures

Figure Liposomal Doxorubicin Picture

Table Product Specifications of Liposomal Doxorubicin

Figure Global Sales Market Share of Liposomal Doxorubicin by Types in 2017

Please fill the form below, to recieve the report sample


+1

Choose License Type

Reach Us

Email us at

sales@mrinsights.biz

Or call us on

US +1-201-465-4211

IND +91-906-779-0957

Why Choose Us

ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems

Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system

Global Outreach6 Major regions and 40+ countries level analysis accomplished

Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery